Literature DB >> 3928818

Intraventricular 5,7-dihydroxytryptamine increases thyrotropin-releasing hormone content in regions of rat brain.

S Manaker, T M Engber, P B Knight, A Winokur.   

Abstract

Rats received intraventricular (i.v.t.) injections of 5,7-dihydroxytryptamine (5,7-DHT) (100-600 micrograms). Some animals also received intraperitoneal injections of the 5-hydroxytryptamine uptake blocker fluoxetine (FX) (20 mg/kg) or the norepinephrine uptake blocker desmethylimipramine (DMI) (48 mg/kg) 30-90 min prior to i.v.t. 5,7-DHT. Rats were killed between 2 and 35 days following i.v.t. 5,7-DHT, brains were dissected, and regions were assayed for thyrotropin-releasing hormone (TRH) by radioimmunoassay. Dose-dependent increases in TRH content following i.v.t. 5,7-DHT were noted in the brainstem and hippocampus. DMI pretreatment blocked the increase in hippocampal TRH, but not in brainstem TRH. FX pretreatment was ineffective in blocking any increases in TRH content. These results suggest differential regulation of regional TRH content by interactions with specific neurotransmitter systems.

Entities:  

Mesh:

Substances:

Year:  1985        PMID: 3928818     DOI: 10.1111/j.1471-4159.1985.tb05561.x

Source DB:  PubMed          Journal:  J Neurochem        ISSN: 0022-3042            Impact factor:   5.372


  3 in total

1.  Neuromodulator role of luliberin in the regulation of sexual behavior in the male rat.

Authors:  V N Babichev; E I Adamskaya; T V El'tseva
Journal:  Neurosci Behav Physiol       Date:  1991 Jul-Aug

2.  Involvement of 5-HT2 receptors in the behaviours produced by intrathecal administration of selected 5-HT agonists and the TRH analogue (CG 3509) to rats.

Authors:  K C Fone; J V Johnson; G W Bennett; C A Marsden
Journal:  Br J Pharmacol       Date:  1989-03       Impact factor: 8.739

Review 3.  Attenuation of kindled seizures by intranasal delivery of neuropeptide-loaded nanoparticles.

Authors:  Michael J Kubek; Abraham J Domb; Michael C Veronesi
Journal:  Neurotherapeutics       Date:  2009-04       Impact factor: 7.620

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.